National Institute on Drug Abuse (NIDA) — CureCurrent

How to interpret these research links

Connected source records

The exact organization name National Institute on Drug Abuse (NIDA) appears in 570 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials570

Recruiting shown24

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

Defining Neurobiological Links Between Substance Use and Mental IllnessNCT05538910 · lead sponsor · 2023-02-02

Olfactory Function and Model-Based Behavior in People Living With HIV and SUDNCT07637669 · lead sponsor · 2026-10-12

NOT_YET_RECRUITING

Health Outcomes by Neighborhood - BaltimoreNCT01571752 · lead sponsor · 2012-07-17

Brain Functions Underlying Visuospatial Attention Deficits in SchizophreniaNCT01399437 · lead sponsor · 2011-07-03

Brain Circuits in Schizophrenia and SmokingNCT01369966 · lead sponsor · 2011-05-16

Nicotinic Receptor Density in Smoking and Nonsmoking SchizophrenicsNCT01246128 · lead sponsor · 2010-10-31

Effects of Antipsychotics on Eating and Food Craving in People With SchizophreniaNCT01222793 · lead sponsor · 2010-09-26

Assessment of Cannabis Craving in Schizophrenia Using Virtual RealityNCT01212081 · lead sponsor · 2010-09-26

Risk Perception in Drug-Dependent Adults With and Without SchizophreniaNCT01031563 · lead sponsor · 2009-08-18

Assessment of Craving in Nicotine-Dependent Patients With Schizophrenia Using Virtual RealityNCT01031433 · lead sponsor · 2009-07-28

Effects of Nicotine on Areas of Impaired and Preserved Functioning in SchizophreniaNCT01034085 · lead sponsor · 2009-06-02

Aripiprazole for Prevention of Relapse to Cocaine Use in Methadone-Maintenance PatientsNCT00780702 · lead sponsor · 2008-05-08

Multi-Level HIV Prevention for Pregnant Drug AbusersNCT01976702 · lead sponsor · 2006-10-01

The Neuropsychiatric Evaluation of HIV-Positive and Negative Drug Using Individuals: Study 215NCT01034800 · lead sponsor · 2006-09-01

Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug DependenceNCT01037075 · lead sponsor · 2006-05-14

Neuroimaging Studies of Neurophysiological Phenotypes in SchizophreniaNCT01036568 · lead sponsor · 2006-02-14

Assessing the Variability Over Time of Tobacco Carcinogen Biomarkers in Smokers - 2NCT00158145 · lead sponsor · 2005-09-01

Dopamine Function and Reward Processing In SchizophreniaNCT01035996 · lead sponsor · 2005-03-08

fMRI Study of Nicotinic Effect on Neurophysiology of SchizophreniaNCT01046526 · lead sponsor · 2005-02-08

Treatment of Heroin and Cocaine With Methadone Maintenance and Contingency ManagementNCT00292110 · lead sponsor · 2004-02-01

Effect of Bupropion on Smoking Behavior in Smokers With SchizophreniaNCT00218231 · lead sponsor · 2004-01-01

Preventing Depression in Methadone Maintenance Patients Receiving Hepatitis C Treatment - 1NCT00218556 · lead sponsor · 2004-01-01

An Hepatitis B Vaccine Model for HIV Vaccine Trials in Drug UsersNCT00841477 · lead sponsor · 2004-01-01

Positive Choice: Prevention for Positive HealthNCT00447707 · lead sponsor · 2003-12-01

Nicotine and Cotinine Levels in Smokers With Schizophrenia and Schizoaffective Disorder - 2NCT00135772 · lead sponsor · 2003-10-01

Chronic Hepatitis Intervention Project for Drug UsersNCT00596843 · lead sponsor · 2003-09-01

Physician Focused Intervention to Improve Adherence With HIV AntiretroviralsNCT00870792 · lead sponsor · 2002-11-01

Study to Reduce Intravenous Exposures (STRIVE)NCT00391482 · lead sponsor · 2002-06-01

Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With SchizophreniaNCT00218218 · lead sponsor · 2002-06-01

The Aim of This Study is to Determine the Effectiveness of a Motivational Enhancement Intervention in Reducing Risk Behaviors (Drug and Alcohol Use, Sexual Risk Behavior, Poor Adherence to Medications) Among HIV+ Youth. - 1NCT00227825 · lead sponsor · 2002-01-01

Comparing the Effects of Smoked and Oral Marijuana in Individuals With HIV/AIDSNCT00079560 · lead sponsor · 2001-12-01

Treating Nicotine Dependence in Schizophrenic Individuals: Effectiveness of Bupropion - 1NCT00124683 · lead sponsor · 2001-09-01

Nicotine Patch for Nicotine Dependence in Individuals With Schizophrenia or Schizoaffective Disorder - 1NCT00046813 · lead sponsor · 2001-08-01

Integrated Treatment for Cocaine and Mood Disorders - 1NCT00227812 · lead sponsor · 2001-04-01

Cognitive Behavioral Stress Management for HIV+ Drug AbusersNCT00722644 · lead sponsor · 1999-09-01

Motivation and Patch Treatment for HIV-positive SmokersNCT00551720 · lead sponsor · 1999-01-01

Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who SmokeNCT00307203 · lead sponsor · 1998-08-01

Project SHIELD 2.0: Police Education to Support Public Health in KentuckyNCT07804121 · collaborator · 2026-06-25

CHAMPION: Combining HIV And Meth Prevention and Treatment Interventions Optimized for HIV-Negative MSMNCT07213258 · collaborator · 2026-04-24

The Trans-Led Care StudyNCT06880705 · collaborator · 2026-04-14

Mindfulness Training During Accelerated TMS for DepressionNCT07369557 · collaborator · 2026-04-13

Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis UseNCT06878859 · collaborator · 2026-02-23

Reactive Driven Support for Treatment, Adherence, Resilience, and Thriving (reSTART) Clinical TrialNCT07125235 · collaborator · 2026-02-09

HIV, Equity, and Addiction Training (HEAT) ProgramNCT06370481 · collaborator · 2026-01-29

Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy VolunteersNCT07349758 · collaborator · 2026-01-06

California MEPS HubNCT07433985 · collaborator · 2025-12-01

Shared Decision Making to Treat Or Prevent (STOP) HIV in Criminal Legal Involved Populations (R33)NCT07223398 · collaborator · 2025-11-24

Behavioral Activation and Risk Reduction for Stimulant Use Among Sexually Active Adolescents and Young AdultsNCT06444360 · collaborator · 2025-11-04

Syringe Service Based Telemedicine and Social Network Driven HIV Prevention Service ImplementationNCT06103370 · collaborator · 2025-10-28

Feasibility of Internet-based HIV Prevention ResearchNCT07625917 · collaborator · 2025-08-01

Project Vuselela FeasibilityNCT07117656 · collaborator · 2025-07-13

Advancing Access to HIV/HCV Testing for People Who Inject Drugs (PWID)NCT06730555 · collaborator · 2025-06-27

Project neuroARTEMISNCT06814275 · collaborator · 2025-04-29

Naltrexone for Overdose PreventionNCT06633900 · collaborator · 2025-04-10

Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug UseNCT06829238 · collaborator · 2025-04-07

Mitigating the Impact of Stigma and Shame Among People Living With HIV and Substance Use DisordersNCT05934305 · collaborator · 2025-03-12

reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)NCT05958017 · collaborator · 2025-03-04

Behavioral Economic Intervention to Improve HIV Behaviors in Sexual Minority IndividualsNCT06745947 · collaborator · 2025-03-03

Vaping and Smoking Project in People With SchizophreniaNCT06944847 · collaborator · 2025-02-15

Stress and Pain in People Living With HIVNCT06784908 · collaborator · 2025-01-16

Drugs studied in this sponsor's trials

45 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing National Institute on Drug Abuse (NIDA) as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

placebo27

methadone8

buprenorphine7

bupropion7

varenicline7

dronabinol4

buprenorphine / naloxone3

naltrexone3

placebo RxCUI 8375 · Lead sponsor in 1 linked trial(s) · 3 currently recruiting 27 trials methadone RxCUI 6813 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 8 trials buprenorphine RxCUI 1819 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 7 trials bupropion RxCUI 42347 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 7 trials varenicline RxCUI 591622 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 7 trials dronabinol RxCUI 10402 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 4 trials buprenorphine / naloxone RxCUI 352364 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 3 trials naltrexone RxCUI 7243 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 3 trials placebo Oral Tablet RxCUI 375221 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 3 trials fluoxetine RxCUI 4493 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials lorcaserin RxCUI 1300701 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials mirtazapine RxCUI 15996 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials nevirapine RxCUI 53654 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials raltegravir RxCUI 719872 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials acyclovir RxCUI 281 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial ampicillin sodium RxCUI 81953 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial aripiprazole RxCUI 89013 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial buprenorphine Injection RxCUI 1729358 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial bupropion hydrochloride RxCUI 203204 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial cabotegravir Injection RxCUI 2588076 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial cannabidiol Oral Solution RxCUI 2058899 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial clozapine RxCUI 2626 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial disulfiram RxCUI 3554 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial dronabinol Oral Capsule RxCUI 371971 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

collaborator533

lead sponsor37

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.